Observed Zepbound price anchor maintenance_self_pay
Observed Zepbound maintenance_self_pay at $449/month from Zepbound Savings.
tirzepatide · GIP/GLP-1 receptor agonist
Manual-verified official Lilly anchors while backend fetch remains blocked.
Manual verified
Basis split
Lilly publishes a label-safe prescribing-information result and a rounded consumer headline. Keep the label anchor as the comparable clinical number and keep the headline as attributed context.
2 anchors
Trial: Study 1
Adults without diabetes
Mean body-weight change at Week 72 for 15 mg in Study 1.
Dose context: 15 mg
Trial: Consumer/HCP headline
Rounded consumer-facing headline
Rounded consumer-facing efficacy claim of about 21%.
Dose context: highest dose
3 anchors
Dose context: 2.5 mg
Program: Self Pay Journey Program
Current self-pay program pricing for 2.5 mg.
Official starting self-pay program price
Patient segment: cash_pay
Starting price under current self-pay program.
Dose context: 5 mg
Program: Self Pay Journey Program
Step-up self-pay program price for 5 mg.
Current self-pay program pricing for 5 mg.
Patient segment: cash_pay
Intermediate self-pay program price for 5 mg.
Dose context: 7.5 mg, 10 mg, 12.5 mg, 15 mg
Program: Self Pay Journey Program
Maintenance self-pay program price for 7.5 mg and above.
Current self-pay program pricing for higher maintenance doses.
Patient segment: cash_pay
Current maintenance self-pay price for higher doses.
3 linked
backs: Starting self-pay, Step-up self-pay, Maintenance self-pay
backs: Consumer headline
backs: Label-safe anchor
Timeline
Observed Zepbound maintenance_self_pay at $449/month from Zepbound Savings.
Observed Zepbound step_up_self_pay at $399/month from Zepbound Savings.
Observed Zepbound starting_self_pay at $299/month from Zepbound Savings.
Observed Zepbound company_headline efficacy anchor at 21% from What Is Zepbound?.
Observed Zepbound label_absolute efficacy anchor at 20.9% from Zepbound Prescribing Information.